葛兰素史克Glaxosmithkline（GSK）2025年第二季度财报电话会议纪要「LSE」（英文版）（27页）.pdf

1、 Investor Relations Q2 2025 results presentation Page 1 of 27 Wednesday,Wednesday,3 30 0 JulyJuly 2022025 5 at 1at 12 2:00:00 BSTBST Introduction|Constantin Fest Slide 1|Q2 2025 Results Slide 2|Agenda Ladies and gentlemen,a very warm welcome to the GSK Q2 2025 results call.I am delighted to be joine

2、d today by Emma Walmsley,Tony Wood,Luke Miels,Deborah Waterhouse and Julie Brown,with David Redfern joining for Q&A.Todays call will last approximately one hour with the presentation taking around 30 minutes and the remaining time for your questions.Please ask only 1-2 questions so that everyone has

3、 a chance to participate.Before we start,please turn to slide 3.Slide 3|Cautionary statement regarding forward-looking statements This is the usual safe-harbour statement.We will comment on our performance using constant exchange rates or CER unless otherwise stated.I will now hand over to Emma on s

4、lide 4.Q2 2025 Performance Momentum|Emma Walmsley Slide 4|Q2 2025 Performance Momentum Thank you and welcome to everybody joining us today.Please turn to the next slide.Slide 5|2025 performance momentum:Q2 Highlights Our second quarter results once again demonstrate GSKs strong performance momentum-

5、and the quality and strength of our portfolio.Group sales were up 6%for the quarter,core operating profit was up 12%,and core earnings per share grew 15%to 46.5 pence.Sales growth was driven by our largest business,Specialty Medicines,up 15%.And Vaccine sales also contributed with sales up 9%in the

6、quarter.This led to increases in profits and earnings,which also benefitted from a strong focus on SG&A.Alongside operating performance,we continue to make good progress in R&D,with 3 FDA approvals achieved so far this year.Investor Relations Q2 2025 results presentation Page 2 of 27 Cash generation